{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:47:40Z","timestamp":1760150860614,"version":"build-2065373602"},"reference-count":41,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T00:00:00Z","timestamp":1643500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Despite three randomized trials indicating a significant reduction in biochemical recurrence (BCR) in high-risk patients, adjuvant radiotherapy (aRT) was rarely performed, even in patients harboring high-risk features. aRT is associated with a higher risk of urinary incontinence and is often criticized for the lack of patient selection criteria. With a BCR rate reaching 30\u201370% in high-risk patients, a consensus between urologists and radiation oncologists was needed, leading to three different randomized trials challenging aRT with early salvage radiotherapy (eSRT). In these three different randomized trials with event-free survival as the primary outcome and a planned meta-analysis, eSRT appeared as non-inferior to aRT, answering, for some, this never-ending question. For many, however, the debate persists; these results raised several questions among urologists and radiation oncologists. BCR is thought to be a surrogate for clinically meaningful endpoints such as overall survival and cancer-specific survival but may be poorly efficient in comparison with metastasis-free survival. Imaging of rising prostate-specific antigen (PSA), post-operative persistent PSA and BCR was revolutionized by the broader use of MRI and nuclear imaging such as PET-PSMA; these imaging modalities were not analyzed in the previous randomized trials. A sub-group of very high-risk patients could possibly benefit from an adjuvant radiotherapy; but their usual risk factors such as high Gleason score or invaded surgical margins mean they are unable to be selected. More precise biomarkers of early BCR or even metastatic-relapse were developed in this setting and could be useful for the patients\u2019 stratification. In this review, we insist on the need for multidisciplinary discussions to fully comprehend the individual characteristics of each patient and propose the best treatment strategy for every patient.<\/jats:p>","DOI":"10.3390\/cancers14030719","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T01:46:08Z","timestamp":1643593568000},"page":"719","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Narrative Review of the Post-Operative Management of Prostate Cancer Patients: Is It Really the End of Adjuvant Radiotherapy?"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2631-0029","authenticated-orcid":false,"given":"Vincent","family":"Bourbonne","sequence":"first","affiliation":[{"name":"Radiation Oncology Department, University Hospital, 29200 Brest, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Pradier","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, University Hospital, 29200 Brest, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Schick","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, University Hospital, 29200 Brest, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(12)61253-7","article-title":"Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: Long-term results of a randomised controlled trial (EORTC trial 22911)","volume":"380","author":"Bolla","year":"2012","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2002.01.150","article-title":"Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: A large single-institution experience with radical prostatectomy and external-beam radiotherapy","volume":"20","author":"Kupelian","year":"2002","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0022-5347(05)63946-8","article-title":"Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer","volume":"169","author":"Han","year":"2003","journal-title":"J. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.juro.2008.11.032","article-title":"Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term followup of a randomized clinical trial","volume":"181","author":"Thompson","year":"2009","journal-title":"J. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2014.03.011","article-title":"Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02\/AUO AP 09\/95 trial","volume":"66","author":"Wiegel","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): A randomised, phase 3 trial","volume":"21","author":"Sargos","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): A randomised, controlled, phase 3, non-inferiority trial","volume":"21","author":"Kneebone","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","article-title":"Timing of radiotherapy after radical prostatectomy (RADICALS-RT): A randomised, controlled phase 3 trial","volume":"396","author":"Parker","year":"2020","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","article-title":"Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: A prospectively planned systematic review and meta-analysis of aggregate data","volume":"396","author":"Vale","year":"2020","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1001\/jamaoncol.2020.7671","article-title":"Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG\/RTOG 9601 Randomized Clinical Trial","volume":"7","author":"Feng","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1200\/JCO.2006.08.9607","article-title":"Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy","volume":"25","author":"Stephenson","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_12","first-page":"CD007234","article-title":"Adjuvant radiotherapy following radical prostatectomy for prostate cancer","volume":"12","author":"Daly","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2008.04.013","article-title":"Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: A systematic review and meta-analysis","volume":"88","author":"Morgan","year":"2008","journal-title":"Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.eururo.2019.07.001","article-title":"Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension","volume":"76","author":"Hackman","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.clgc.2020.05.001","article-title":"A Nationwide Persistent Underutilization of Adjuvant Radiotherapy in North American Prostate Cancer Patients","volume":"18","author":"Rakic","year":"2020","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.juro.2016.09.079","article-title":"Early Postoperative Radiotherapy is Associated with Worse Functional Outcomes in Patients with Prostate Cancer","volume":"197","author":"Zaffuto","year":"2017","journal-title":"J. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.eururo.2016.07.028","article-title":"Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series","volume":"71","author":"Fossati","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.1002\/cncr.26169","article-title":"The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy","volume":"117","author":"Cooperberg","year":"2011","journal-title":"Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.eururo.2012.10.036","article-title":"Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: A long-term survival analysis","volume":"63","author":"Abdollah","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.21037\/tau-20-1031","article-title":"Narrative review of management strategies and outcomes in node-positive prostate cancer","volume":"10","author":"Chen","year":"2021","journal-title":"Transl. Androl. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1200\/JCO.2013.54.7893","article-title":"Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer","volume":"32","author":"Abdollah","year":"2014","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2018.04.017","article-title":"Impact of Adjuvant Radiotherapy in Node-positive Prostate Cancer Patients: The Importance of Patient Selection","volume":"74","author":"Abdollah","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.eururo.2017.09.027","article-title":"Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies","volume":"73","author":"Touijer","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.eururo.2017.11.020","article-title":"Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series","volume":"73","author":"Gandaglia","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2020.0109","article-title":"Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer","volume":"6","author":"Dess","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.urolonc.2019.09.018","article-title":"Androgen deprivation therapy in men with node-positive prostate cancer treated with postoperative radiotherapy","volume":"38","author":"Bravi","year":"2020","journal-title":"Urol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.eururo.2013.03.029","article-title":"Phase 3 study of adjuvant radiotherapy versus wait and see in pT3 prostate cancer: Impact of pathology review on analysis","volume":"64","author":"Bottke","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.eururo.2013.04.002","article-title":"Central prostate pathology review: Should it be mandatory?","volume":"64","author":"Montironi","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"723536","DOI":"10.3389\/fonc.2021.723536","article-title":"A Multi-Institutional Analysis of Prostate Cancer Patients with or without 68Ga-PSMA PET\/CT Prior to Salvage Radiotherapy of the Prostatic Fossa","volume":"11","author":"Zamboglou","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s13014-017-0902-0","article-title":"Detection level and pattern of positive lesions using PSMA PET\/CT for staging prior to radiation therapy","volume":"12","author":"Fendler","year":"2017","journal-title":"Radiat. Oncol."},{"key":"ref_32","first-page":"194","article-title":"Detection Rate and Localization of Prostate Cancer Recurrence Using (68)Ga-PSMA-11 PET\/MRI in Patients with Low PSA Values <\/= 0.5 ng\/mL","volume":"61","author":"Kranzbuhler","year":"2020","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.ijrobp.2020.11.010","article-title":"Prostate Bed Delineation Guidelines for Postoperative Radiation Therapy: On Behalf Of The Francophone Group of Urological Radiation Therapy","volume":"109","author":"Robin","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1148\/rg.2019180079","article-title":"Revisiting Prostate Cancer Recurrence with PSMA PET: Atlas of Typical and Atypical Patterns of Spread","volume":"39","author":"Barbosa","year":"2019","journal-title":"Radiographics"},{"key":"ref_35","first-page":"1972","article-title":"Treatment Outcomes from (68)Ga-PSMA PET\/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET","volume":"58","author":"Emmett","year":"2017","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1002\/cncr.30665","article-title":"Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study","volume":"123","author":"Gore","year":"2017","journal-title":"Cancer"},{"key":"ref_37","first-page":"1","article-title":"Contemporary Role of the Decipher(R) Test in Prostate Cancer Management: Current Practice and Future Perspectives","volume":"18","author":"Dalela","year":"2016","journal-title":"Rev. Urol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e16122","DOI":"10.1200\/jco.2015.33.15_suppl.e16122","article-title":"Recalibration of genomic risk prediction models in prostate cancer to improve individual-level predictions","volume":"33","author":"Davicioni","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Bourbonne, V., Fournier, G., Vallieres, M., Lucia, F., Doucet, L., Tissot, V., Cuvelier, G., Hue, S., Le Penn Du, H., and Perdriel, L. (2020). External Validation of an MRI-Derived Radiomics Model to Predict Biochemical Recurrence after Surgery for High-Risk Prostate Cancer. Cancers, 12.","DOI":"10.3390\/cancers12040814"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"103163","DOI":"10.1016\/j.ebiom.2020.103163","article-title":"A novel imaging based Nomogram for predicting post-surgical biochemical recurrence and adverse pathology of prostate cancer from pre-operative bi-parametric MRI","volume":"63","author":"Li","year":"2021","journal-title":"EBioMedicine"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1470-2045(20)30730-0","article-title":"Intermediate clinical endpoints for surrogacy in localised prostate cancer: An aggregate meta-analysis","volume":"22","author":"Gharzai","year":"2021","journal-title":"Lancet Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/719\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:11:20Z","timestamp":1760134280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,30]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cancers14030719"],"URL":"https:\/\/doi.org\/10.3390\/cancers14030719","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2022,1,30]]}}}